Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 201 of 5804
-
New hope for rare ovarian cancer: drug shrinks tumors after immunotherapy fails
Disease control Not yet recruitingOvarian clear cell carcinoma (OCCC) is a relatively rare but highly malignant epithelial ovarian cancer, accounting for 5%-10% of all ovarian cancers. The incidence of this tumor has significant racial disparity, with the highest incidence in Asians, accounting for 25% of ovarian…
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 26, 2026 16:50 UTC
-
Can smart breathing devices save more cardiac arrest patients?
Disease control Not yet recruitingCardiac arrest is a life-threatening emergency that requires immediate treatment with cardiopulmonary resuscitation (CPR). While chest compressions circulate blood, manual ventilation provides oxygen to the patient. Current CPR guidelines recommend specific ventilation rates and …
Phase: NA • Sponsor: Rush University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
First human trial launches for brain cancer vaccine
Disease control Not yet recruitingThe objectives of this phase I first-in-human trial are to evaluate safety, feasibility, and preliminary efficacy of an individualized Bvax vaccine in addition to standard of care chemoradiation in patients with newly diagnosed glioblastoma.
Phase: PHASE1 • Sponsor: Catalina Lee Chang • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Lung cancer showdown: surgery vs. radiation in High-Risk patients
Disease control Not yet recruitingIn low-risk patients with stage I non-small cell lung cancer (NSCLC) surgical treatment with an anatomical resection is currently the standard of care. For medically inoperable patients with stage I NSCLC, radiation therapy is currently the standard treatment. The latest generat…
Phase: NA • Sponsor: Aarhus University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New combo aims to stop leukemia return in older patients
Disease control Not yet recruitingAfter remission post-induction and consolidation, maintenance therapy by an ivosidenib and oral azacitidine combination is susceptible to improve the prevention of AML relapse, which remains a major issue in the study population. We assume that the combination of ivosidenib with …
Phase: PHASE2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New triple drug combo aims to slash cholesterol after heart attacks
Disease control Not yet recruitingEarly and intensive LDL-cholesterol (LDL-c) reduction is associated with improved short-term and long-term outcomes. Bempedoic acid is an oral ATP citrate lyase inhibitor that lowers LDL-c upstream of HMG-CoA reductase. When added to maximally tolerated statins, it has demonstrat…
Phase: PHASE3 • Sponsor: Heart Care Foundation • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New pill could help kids with thalassemia fight anemia without transfusions
Disease control Not yet recruitingThe primary objective of this study is to compare the effect of mitapivat versus placebo on anemia in pediatric participants with alpha- or beta-non-transfusion-dependent thalassemia.
Phase: PHASE3 • Sponsor: Agios Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could CAR-T cells tame autoimmune diseases? early safety trial launches
Disease control Not yet recruitingThis is an open-label, single-dose, prospective, monocenter, Phase I interventional study (not first-in-human) to assess the safety, tolerability, and preliminary efficacy of autologous anti-CD19 CAR-T cells as an advanced therapy medicinal product in adult patients; with severe …
Phase: PHASE1 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Chemo-free triplet aims to outsmart incurable lymphoma
Disease control Not yet recruitingFollicular lymphoma (FL) remains an incurable indolent B-cell lymphoma for many patients, and although rituximab-based chemoimmunotherapy can achieve high initial response rates, a substantial proportion of patients experience early progression, including POD24, which is associat…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Engineered immune cells take on brain cancer in early trial
Disease control TerminatedCentral nervous system lymphoma (CNSL) includes primary CNS lymphoma (PCNSL) and secondary CNS lymphoma (SCNSL), with diffuse large B-cell lymphoma as the predominant pathological type. Disease progression is often rapid and the relapse rate is high. Current standard treatment is…
Phase: PHASE1 • Sponsor: Beijing Boren Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New CPR technique could save more newborn lives
Disease control Not yet recruitingNewborn infants who require cardiopulmonary resuscitation at birth receive chest compression using a 3-Compression to 1-Ventilation (3:1 C:V) ratio. However, the optimal chest compression technique during cardiopulmonary resuscitation is uncertain and identified as a critical gap…
Phase: NA • Sponsor: University of Alberta • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could the time of day you get immunotherapy boost its power against melanoma?
Disease control Not yet recruitingMelanoma remains a common cancer with rising incidence, and despite significant improvements with immune checkpoint inhibitors (ICIs), clinical outcomes remain heterogeneous. Retrospective analyses across multiple tumor types, including melanoma, suggest that earlier daytime admi…
Phase: PHASE4 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New combo shows promise for Tough-to-Treat uterine cancer
Disease control Recruiting nowThe purpose of this study is to determine the efficacy and safety of Pembrolizumab in combination with Lenvatinib in recurrent, mismatch repair-proficient endometrial cancer after failure of first-line therapy with a platinum-based doublet chemotherapy and immunotherapy.
Phase: PHASE2 • Sponsor: University of Miami • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Off-the-Shelf CAR-Ts take on lupus and more
Disease control Not yet recruitingThis is a single-arm, open-label, investigator-initiated trial (IIT) designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RD06-05 in patients with autoantibody-mediated autoimmune diseases. The enrolled population consists of patients …
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New hope for hard-to-treat prostate cancer: drug combo trial launches
Disease control Not yet recruitingThis study will first conduct a phase II clinical study, and on the basis of the phase II clinical study, subsequent clinical research will be carried out.
Phase: PHASE2, PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
30,000 seniors to wear heart patches in massive Stroke-Prevention study
Diagnosis Not yet recruitingThis prospective, multicenter, single-arm study evaluates the effectiveness of a single-lead patch electrocardiogram (ECG) recorder in screening for atrial fibrillation (AF) among community-dwelling elderly individuals aged ≥60 years in China. Participants will undergo 7 days of …
Phase: NA • Sponsor: Beijing Anzhen Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 13:04 UTC
-
New antibody drug aims to save Insulin-Making cells in type 1 diabetes
Disease control Not yet recruitingThis Phase 3, multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy, safety, and tolerability of SAB-142, a fully human anti-thymocyte globulin (h-ATG), in participants aged 5 to 40 years with Stage 3 type 1 diabetes (T1D). The study will enro…
Phase: PHASE3 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Spinal stimulation may steady blood pressure after spinal cord injury
Disease control Not yet recruitingThe purpose of this study is to learn whether stimulation applied to the spinal cord through the skin (called transcutaneous spinal stimulation) can help control blood pressure in people with a spinal cord injury. The main questions this study attempts to solve: 1. What are the…
Phase: NA • Sponsor: Kessler Foundation • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Tailored breathing support may reduce lung injury in ECMO patients
Disease control Not yet recruitingWhile mechanical ventilation can be used to sustain life in those with lung injury, it, can further worsen lung injury or prevent lung healing resulting in high morbidity and mortality as seen in Acute Respiratory Distress Syndrome (ARDS). Using extracorporeal membrane oxygenati…
Phase: NA • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could a fibroid drug help women with adenomyosis finally achieve a live birth?
Disease control Not yet recruitingAdenomyosis is associated with impaired endometrial receptivity and reduced implantation rates in assisted reproduction, even when using high-quality embryos. Linzagolix (Yselty, 200 mg) is an oral GnRH receptor antagonist approved for uterine fibroids with a favourable tolerabil…
Sponsor: Vida Fertility Institute • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC